➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Moodys
Baxter
McKesson
Johnson and Johnson
AstraZeneca
Mallinckrodt

Last Updated: June 15, 2021

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR LINSITINIB


Email this page to a colleague

« Back to Dashboard

Clinical Trials for Linsitinib

Trial ID Title Status Sponsor Phase Summary
NCT00924989 A Study of OSI-906 in Patients With Locally Advanced or Metastatic Adrenocortical Carcinoma Completed Astellas Pharma Inc Phase 3 A multicenter, randomized, double-blind, placebo-controlled, phase 3 study of single-agent OSI-906 in patients with locally advanced/metastatic Adrenocortical Carcinoma (ACC) who received at least 1 but no more than 2 prior drug regimens
NCT01016860 OSI-906 and Irinotecan in Patients With Advanced Cancer Terminated University of Colorado, Denver Phase 1 This study plans to learn more about an investigational drug called OSI-906. OSI-906 is being looked at to see if it could be a treatment for advanced cancer. "The FDA is the U.S. government agency that reviews the results of research of drugs and decides if it can be sold in the U.S. OSI-906 has been given to over 185 people with cancer.
NCT01465815 Phase I/II Study of Postoperative Adjuvant Chemoradiation for Advanced-Stage Cutaneous Squamous Cell Carcinoma of the Head and Neck (cSCCHN) Withdrawn National Cancer Institute (NCI) Phase 1/Phase 2 This phase I/II trial studies the side effects and best dose of linsitinib when given together with erlotinib hydrochloride and radiation therapy after surgery in treating patients with advanced or recurrent head and neck cancer. Erlotinib hydrochloride and linsitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Radiation therapy uses high-energy x-rays to kill tumor cells. Giving radiation therapy together with erlotinib hydrochloride and linsitinib may kill more tumor cells. Giving these treatments after surgery may kill any tumor cells that remain after surgery.
>Trial ID >Title >Status >Phase >Summary

Clinical Trial Conditions for Linsitinib

Condition Name

Condition Name for
Intervention Trials
Recurrent Prostate Cancer 1
Squamous Cell Carcinoma of the Skin 1
Advanced Solid Tumors 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for
Intervention Trials
Carcinoma 2
Small Cell Lung Carcinoma 1
Gastrointestinal Stromal Tumors 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Linsitinib

Trials by Country

Trials by Country for
Location Trials
United States 35
Germany 3
Netherlands 2
Singapore 2
Italy 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for
Location Trials
Maryland 3
Michigan 3
Florida 3
California 3
Ohio 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Linsitinib

Clinical Trial Phase

Clinical Trial Phase for
Clinical Trial Phase Trials
Phase 3 1
Phase 2 5
Phase 1/Phase 2 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for
Clinical Trial Phase Trials
Completed 4
Active, not recruiting 2
Withdrawn 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Linsitinib

Sponsor Name

Sponsor Name for
Sponsor Trials
National Cancer Institute (NCI) 4
Astellas Pharma Inc 2
European Organisation for Research and Treatment of Cancer - EORTC 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for
Sponsor Trials
Other 6
NIH 4
Industry 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Baxter
Colorcon
AstraZeneca
McKesson
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.